Drug intelligence / Profile preview

GI-19000

Development stage: Preclinical
Lead developer: GlobeImmune

Overview

GI-19000 is a biological product initially developed by GlobeImmune. It is being investigated for the treatment of infectious diseases, with its primary indication being tuberculosis. As of June 2024, the drug remains in preclinical development and has not entered clinical trials or received regulatory approval. The mechanism of action and specific biological target have not been publicly disclosed[1][2].

Other names: GI-19000GI19000GI 19000

Beyond the preview

Go deeper on GI-19000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI-19000.

Explore the full profile